APRETUDE 600 mg, suspension for injection with extended release bottle, 3 ml
Active ingredients: Cabotegravir
Commercialized according to BDPMDispensing in France: Prescription only
Suspension for injection with extended releasebottle, 3 mlintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- APRETUDE 600 mg, suspension injectable à libération prolongée
- Pharmaceutical form
- suspension injectable à libération prolongée
- Route of administration
- intramusculaire
- Presentation description
- 1 flacon(s) en verre brun de 3 ml
- Marketing authorisation holder
- VIIV HEALTHCARE (PAYS-BAS)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 2 Mar 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
62595850CIP73027899CIP133400930278994Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CABOTÉGRAVIRsuspension | 600 mg · un flacon de 3 mL de suspension | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.